FDC Limited has resubmitted press release dated May 27, 2026, titled "Press Release on Q4 - FY 2025-26 and 12M - FY 2025-26 Results".
FDC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
FDC Limited resubmitted its Q4 FY26 results press release correcting a typographical error in the subject line, with no change to actual content. The company reported strong Q4 FY26 performance with revenue of Rs. 585 crores, up 18.9% Y-o-Y, driven by robust growth across all segments. EBITDA surged 97% to Rs. 106 crores with margins expanding to 18.2% from 11.0% last year. PAT more than doubled to Rs. 103 crores. For full year FY26, revenue stood at Rs. 2,171 crores (up 3%) with PAT of Rs. 281 crores (up 5.5%). Export Formulations led growth with 99.3% Y-o-Y increase in Q4, while US business supplies grew 165.1%. The company received US FDA approval for Fluconazole Tablets during the quarter.
The resubmission was purely procedural to correct a typographical error with no impact on shareholders. Strong Q4 performance with near-doubling of EBITDA margins and 167% PAT growth indicates operational efficiency improvements, particularly in the US business which overcame earlier challenges. FY26 full-year revenue growth of 3% was muted due to flat domestic formulations performance, but improving export momentum provides positive outlook.